Garland Green, MD
Interventional Cardiology · Baton Rouge, LANPI 1811044795
Payments from drug & device makers
Across 587 payments — averaging $62.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$13K
- Boston Scientific$5K
- Abiomed$4K
- Edwards Lifesciences$3K
- Abbott$1K
- Shockwave Medical, Inc$1K
- plus $8K from 53 others
What the payments were for
- Travel & lodging$14,38039%
- Food & beverage$22,38561%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$9,660
- Impella$3,224
- Edwards SAPIEN 3 Transcatheter Heart Valve$2,114
- GENERAL - THERAPIES$1,094
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,059
- CoreValve Evolut$868
- Avalus$513
- SYNERGY ABLATION SYSTEM$446
- ATRICURE CRYOICE CRYOSPHERE CRYOABLATION SYSTEM$446
- FLOWTRIEVER CATHETER, S$445
- 3F$444
- On-X$398
- SYMPLICITY G3$280
- AVVIGO Guidance System$250
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$242
- GENERAL - STRUCTURAL HEART$239
- MitraClip$238
- Repatha$235
- VENOVO$160
- Penumbra System$159
How this compares
$36,777 in reported general payments places this provider in the 70th percentile of 171 interventional cardiology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 384 | $385,658 |
| EntrestoSacubitril/Valsartan | 308 | $382,501 |
| JardianceEmpagliflozin | 82 | $93,234 |
| FarxigaDapagliflozin Propanediol | 68 | $85,452 |
| Repatha SureclickEvolocumab | 75 | $66,374 |
| XareltoRivaroxaban | 36 | $48,315 |
| BrilintaTicagrelor | 55 | $47,341 |
| OzempicSemaglutide | 11 | $19,829 |
| Nebivolol Hcl | 232 | $15,390 |
| NexlizetBempedoic Acid/Ezetimibe | 14 | $15,296 |
| Atorvastatin Calcium | 1,267 | $14,646 |
| Ranolazine ErRanolazine | 135 | $13,930 |
| NexletolBempedoic Acid | 17 | $13,774 |
| Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine | 50 | $12,502 |
| Rosuvastatin Calcium | 625 | $8,931 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $460 | $385,658384 claims |
| NovartisEntresto | $436 | $382,501308 claims |
| AstraZenecaFarxiga, Brilinta | $244 | $132,792123 claims |
| Boehringer IngelheimJardiance | $128 | $93,23482 claims |
| Johnson & JohnsonXarelto | $366 | $48,31536 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $19 | $29,07031 claims |
| Novo NordiskOzempic | $178 | $19,82911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 171 interventional cardiology providers in Louisiana.
Other interventional cardiology in Baton Rouge
- Denzil MoraesBaton Rouge$1.4M
- Jorge CastellanosBaton Rouge$561K
- Venkata GadiBaton Rouge$132K
- Steven KelleyBaton Rouge$116K
- Andrew ReesBaton Rouge$95K
- Harold HelmkeBaton Rouge$32K
- Lance LamotteBaton Rouge$24K
- Craig WalkerHouma$5.5M
- Naseem JaffraniAlexandria$5.1M
- Mark NapoliMonroe$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.